287 related articles for article (PubMed ID: 21362133)
21. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Ma X; Ezzeldin HH; Diasio RB
Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
[TBL] [Abstract][Full Text] [Related]
22. [Development of HDAC inhibitors].
Sowa Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
[TBL] [Abstract][Full Text] [Related]
23. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
Tan J; Cang S; Ma Y; Petrillo RL; Liu D
J Hematol Oncol; 2010 Feb; 3():5. PubMed ID: 20132536
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.
Lee P; Murphy B; Miller R; Menon V; Banik NL; Giglio P; Lindhorst SM; Varma AK; Vandergrift WA; Patel SJ; Das A
Anticancer Res; 2015 Feb; 35(2):615-25. PubMed ID: 25667438
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
Ververis K; Hiong A; Karagiannis TC; Licciardi PV
Biologics; 2013; 7():47-60. PubMed ID: 23459471
[TBL] [Abstract][Full Text] [Related]
27. Vorinostat in cutaneous T-cell lymphoma.
Duvic M; Vu J
Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
[TBL] [Abstract][Full Text] [Related]
28. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.
Mekala JR; Ramalingam PS; Mathavan S; Yamajala RBRD; Moparthi NR; Kurappalli RK; Manyam RR
Chem Biol Interact; 2022 Apr; 357():109876. PubMed ID: 35283086
[TBL] [Abstract][Full Text] [Related]
30. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
31. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Hymes KB
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
[TBL] [Abstract][Full Text] [Related]
32. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present).
Liu YM; Liou JP
Expert Opin Ther Pat; 2023; 33(5):349-369. PubMed ID: 37249104
[TBL] [Abstract][Full Text] [Related]
33. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
34. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
[TBL] [Abstract][Full Text] [Related]
35. Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects.
Nepali K; Wu AC; Lo WL; Chopra B; Lai MJ; Chuang JY; Liou JP
Eur J Med Chem; 2023 Feb; 248():115054. PubMed ID: 36630883
[TBL] [Abstract][Full Text] [Related]
36. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Kavanaugh SM; White LA; Kolesar JM
Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Khan O; La Thangue NB
Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
[TBL] [Abstract][Full Text] [Related]
39. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
[TBL] [Abstract][Full Text] [Related]
40. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
